title: The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties.
abstract: Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory effects of TIG on cancer depend on several activating signaling pathways and abnormal mitochondrial function in cancer cells. The aim of this review is to summarize the cumulative anti-tumor evidence supporting TIG activity against different cancer types, including acute myeloid leukemia (AML), glioma, non-small cell lung cancer (NSCLC), among others. In addition, the efficacy and side effects of TIG in cancer patients are summarized in detail. Future clinical trials are also to be discussed that will evaluate the security and validate the underlying the tumor-killing properties of TIG.
authors.affiliation: Department of Pathology, Xiangya Hospital, Central South UniversityChangsha, China; Department of Pathology, School of Basic Medicine, Central South UniversityChangsha, China.
authors.forename: Zhijie
authors.initials: Z
authors.lastname: Xu
authors.affiliation: Department of Pharmacy, Xiangya Hospital, Central South UniversityChangsha, China; Institute of Hospital Pharmacy, Central South UniversityChangsha, China.
authors.forename: Yuanliang
authors.initials: Y
authors.lastname: Yan
authors.affiliation: Center for Molecular Medicine, Xiangya Hospital, Key Laboratory of Molecular Radiation Oncology of Hunan Province, Central South University Changsha, China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Pharmacy, Xiangya Hospital, Central South UniversityChangsha, China; Institute of Hospital Pharmacy, Central South UniversityChangsha, China.
authors.forename: Long
authors.initials: L
authors.lastname: Qian
authors.affiliation: Department of Pharmacy, Xiangya Hospital, Central South UniversityChangsha, China; Institute of Hospital Pharmacy, Central South UniversityChangsha, China.
authors.forename: Zhicheng
authors.initials: Z
authors.lastname: Gong
keywords: Akt signaling; anti-cancer effects; clinical trials; mitochondrial function; side effects; tigecycline